Brenzavvy (bexagliflozin) / TheracosBio - LARVOL DELTA

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG) (clinicaltrials.gov) - P1 | N=150 | Recruiting | Sponsor: University of Virginia | Trial completion date: Oct 2026 ➔ Jun 2029 | Trial primary completion date: Mar 2026 ➔ Oct 2027

Trial completion date • Trial primary completion date • Cardiovascular • Coronary Artery Disease

Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database. (PubMed, J Vet Intern Med) - "This study provides a comprehensive safety profile of bexagliflozin and velagliflozin for diabetes in cats. These findings support veterinarians in implementing differentiated risk monitoring and individualized therapeutic decisions in the management of diabetes in cats."

Adverse events • Journal • P4 data • Diabetes • Metabolic Disorders

Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. (PubMed, Daru) - "SGLT2 inhibitors were not associated with a statistically significant increase in any UTI or serious/complicated UTI. These findings support a distinction between lower-grade urinary events and clinically severe urinary infection, and suggest that urinary safety concerns should not be considered equivalent to the established excess risk of external genital infection."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Heart Failure • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • Urology

Real-World Efficacy and Safety of Sodium-Glucose Cotransport 2 Inhibitors in Type 1 Diabetes (ENDO 2026) - " Retrospective analysis of adults with T1DM prescribed SGLT2i (empagliflozin, dapagliflozin, bexagliflozin) with available continuous glucose meter (CGM) data at a university institute (2018-2025). Adjunctive SGLT2i therapy in T1DM demonstrated clinically meaningful improvements in TIR and insulin reduction, particularly for patients with poorer baseline control. However, despite these trends, the results were not statistically significant. Larger, prospective studies with longer follow-up are required to define the long-term risk-benefit profile."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus

Comparison of effectiveness and safety of bexagliflozin and other sodium-glucose cotransporter 2 inhibitors for type 2 diabetes mellitus in adults: systematic review and network meta-analysis of randomized controlled trials. (PubMed, Front Endocrinol (Lausanne)) - "For HbA1c reduction, canagliflozin (300 mg, 100 mg) and empagliflozin 25 mg were more effective than bexagliflozin, while bexagliflozin was comparable to other SGLT2 inhibitors...Bexagliflozin was superior to dapagliflozin 5 mg but slightly inferior to canagliflozin 300 mg for weight loss, while showing comparable efficacy to other SGLT2 inhibitors...Bexagliflozin demonstrates comparable efficacy to most SGLT2 inhibitors in T2DM patients, with a relatively prominent benefit in body weight reduction and a similar safety profile. Canagliflozin 300 mg provides more effective glycemic and weight control."

Clinical • Journal • Retrospective data • Review • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

Bexagliflozin controls hyperinsulinemia in horses with naturally occurring insulin dysregulation: a placebo-controlled crossover trial. (PubMed, J Am Vet Med Assoc) - "Bexagliflozin (0.06 mg/kg, PO, q 24 h) controlled insulin with minimal impact on serum triglycerides in Arabian horses with naturally occurring insulin dysregulation. Treatment with bexagliflozin was effective for the short-term management of naturally occurring insulin dysregulation in horses."

Journal • Dyslipidemia • Hypertriglyceridemia • Metabolic Disorders

Cardiovascular outcomes of novel SGLT2 inhibitors in patients with type 2 diabetes: a network meta-analysis of bexagliflozin, ertugliflozin and sotagliflozin. (PubMed, Diabetes Res Clin Pract) - "In conclusion, bexagliflozin, ertugliflozin, and sotagliflozin reduced the risk of cardiovascular death or hospitalization for heart failure. Bexagliflozin and sotagliflozin may offer additional benefits in preventing the risk of myocardial infarction."

Journal • Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Myocardial Infarction • Type 2 Diabetes Mellitus

Do SGLT2 Inhibitors Influence Parkinson’s Disease Risk? A Meta-analysis of Randomized Trials (AAN 2026) - "No eligible data were found for ertugliflozin, enavogliflozin, henagliflozin, ipragliflozin, luseogliflozin, or tofogliflozin...Subgroup analyses showed no significant effect for individual agents: empagliflozin 10 mg (OR 0.64, 95% CI 0.17–2.43), empagliflozin 25 mg (OR 0.33, 95% CI 0.01–8.15), dapagliflozin 10 mg (OR 0.33, 95% CI 0.09–1.23), sotagliflozin (OR 0.25, 95% CI 0.03–2.24), canagliflozin 100 mg (OR 3.00, 95% CI 0.31–28.81), and bexagliflozin (OR 1.50, 95% CI 0.06–36.99)...Conclusions SGLT2 inhibitors do not significantly alter the risk of PD. These findings support their neurological safety, though longer follow-up and dedicated neurodegenerative outcome trials are warranted."

Retrospective data • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Heart Failure • Metabolic Disorders • Movement Disorders • Nephrology • Parkinson's Disease • Renal Disease • Type 2 Diabetes Mellitus

Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD) (clinicaltrials.gov) - P4 | N=64 | Active, not recruiting | Sponsor: Baylor Research Institute

New P4 trial • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats. (PubMed, J Vet Pharmacol Ther) - "Treatments were well tolerated. These pharmacokinetic data indicate bexagliflozin exhibits rapid absorption, high oral bioavailability, and a half-life compatible with once-daily dosing in cats."

Journal • PK/PD data • Diabetes • Metabolic Disorders

The Chemistry of Gliflozins: Recent Advancements in SGLT-2 Inhibitors. (PubMed, Cardiovasc Hematol Agents Med Chem) - "Gliflozin Dapagliflozin (DAPA), canagliflozin, and bexgliflozin act by blocking the SGLT-2 protein present in both kidneys and induce the excretion of glucose in the form of urine by decreasing its reabsorption. It also reviews key clinical trials by focusing on its safety with manageable side effects such as urinary tract infections. Overall, a comprehensive analysis has underlined the potential of bexagliflozin as a preferred treatment in diabetes management."

Journal • Cardiovascular • Diabetes • Infectious Disease • Metabolic Disorders • Nephrology • Type 2 Diabetes Mellitus

Case Report: Bexagliflozin as an adjunct decongestive strategy in a cat with congestive heart failure and advanced chronic kidney disease. (PubMed, Front Vet Sci) - "Structured safety monitoring-including serial assessment of urinary glucose, blood glucose, and ketones-did not reveal clinically significant adverse events. This case suggests that, in carefully selected cats with CHF and advanced CKD in which conventional diuretic escalation is high risk, SGLT2i may be considered as an adjunct/bridge option for decongestion, with particular emphasis on proactive monitoring for ketone abnormalities and euglycemic ketoacidosis."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertrophic Cardiomyopathy • Metabolic Disorders • Nephrology • Renal Disease • Respiratory Diseases

Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus. (PubMed, J Pharm Bioallied Sci) - "They were randomly given either empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Bexagliflozin, Sotagliflozin (an SGLT2 inhibitor) or liraglutide, Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin (n GLP-1 receptor agonist) to consume for 24 weeks. But GLP-1 agonists are better at helping people lose weight and keep their hearts healthy, so they are also a fantastic choice for people who have these problems. It's crucial to consider what each patient needs and what could go wrong while establishing treatment plans for them."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists (clinicaltrials.gov) - P4 | N=60 | Active, not recruiting | Sponsor: MaryAnn Banerji

New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Evaluating antifibrotic effects of sotagliflozin, bexagliflozin, semaglutide, dulaglutide, and rhBMP-7 compared to nintedanib and pirfenidone, on fibronectin assembly in myofibroblasts: Role in Idiopathic Pulmonary Fibrosis. (ASHP 2025) - No abstract available

Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Comparison chart: Sodium-glucose cotransporter 2 (SGLT2) inhibitors. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Noninsulin drugs for type 2 diabetes. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Rationale and design of the Adipose Dysfunction, Imaging, Physiology, and Outcomes with sodium-glucose cotransporter - 2 inhibitors for Sleep Apnea (ADIPOSA) study. (PubMed, Contemp Clin Trials) - "The ADIPOSA study will identify the mechanisms underlying the effects of SGLT2i on OSA while providing evidence for future investigation to test the efficacy of pharmacologic SGLT2i on OSA prevention and treatment."

Clinical • Journal • CNS Disorders • Diabetes • Genetic Disorders • Inflammation • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Clinical therapeutics in feline medicine: updates for old and new drugs. (PubMed, J Feline Med Surg) - "The clinical use of these agents, available pharmacokinetic and pharmacodynamic data, and reported adverse effects in cats are presented. The information in this article is relevant to all veterinarians who practice feline medicine."

Journal • Review

Efficacy and Safety of Non-Insulin Antidiabetic Drugs in Cats: A Systematic Review. (PubMed, Animals (Basel)) - "The evidence supports a paradigm shift towards SGLT2 inhibitors as a viable oral monotherapy for select cases of FDM. This alters the clinical risk-benefit discussion from preventing hypoglycemia to mitigating eDKA. Significant evidence gaps remain, particularly the lack of high-quality RCTs and data in cats with common comorbidities."

Journal • Review • Amyloidosis • Diabetes • Hypoglycemia • Metabolic Disorders

Cycloadditions as a Sweet Route to 'Double C-Glycosylation'. (PubMed, Biomolecules) - "Pharmaceuticals, such as the antibiotic erythromycin, and sodium-dependent glucose transporter (SGLT1 & SGTL2) inhibitors such as Bexagliflozin (diabetes) and Sotagliflozin (heart disease), are often sugar-decorated (glycosylated). The way in which this "double C-glycosylation" is naturally mediated is not yet known, yet has been speculated on. Here, we report the exploration and development of a potentially biomimetic procedure that utilises intermolecular cycloaddition chemistry to access new "double C-glycosylated" products and enables the creation of bridged polycyclic ethers from a common maltol-derived oxidopyrylium salt precursor."

Journal • Cardiovascular • Diabetes • Heart Failure • Metabolic Disorders

Bexagliflozin on Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Cureus) - "However, there was a significant reduction in systolic blood pressure in the treatment group (MD: -4.2 mmHg; 95% CI: -5.6 to -2.8; p < 0.01). In large placebo-controlled trials, we observed no beneficial effect of bexagliflozin on kidney function, as described with other SGLT2 inhibitors."

Journal • Retrospective data • Review • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Type 2 Diabetes Mellitus

Clinical efficacy and safety of sodium-glucose cotransporter protein-2 (SGLT-2) inhibitor, glucagon-like peptide-1 (GLP-1) receptor agonist, and Finerenone in type 2 diabetes mellitus with non-dialysis chronic kidney disease: a network meta-analysis of randomized clinical trials. (PubMed, Front Pharmacol) - "According to the SUCRA based relative ranking of treatments, Empagliflozin was the most effective in reducing HbA1c and DBP...Liraglutide was the most effective in reducing LDL-C. Bexagliflozin, Canagliflozin were the most effective in reducing SBP and body weight. Finerenone had the lowest incidence of urinary tract infection, Hypoglycemia was the lowest in the Luseogliflozin group. Ertugliflozin was the least likely to cause acute kidney injury...SGLT-2 inhibitors had a preferential glucose-lowering and weight-loss function, GLP-1 receptor agonists had a preferential lowering of LDL-C and blood glucose, and Finereone significantly reduced SBP compared with PBO. Systematic Review Registration: PROSPERO, CRD42024571544."

Clinical • Journal • Retrospective data • Review • Acute Kidney Injury • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Dyslipidemia • Hypoglycemia • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats. (PubMed, Front Vet Sci) - "We also review the available literature regarding other benefits of these drugs in humans as well as the effects of SGLT2i in cats. Adverse effects related to the use of these hypoglycemic drugs are also discussed."

Journal • Review • Cardiovascular • Cognitive Disorders • Diabetes • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

A renal indication for semaglutide (Ozempic). (PubMed, Med Lett Drugs Ther) - No abstract available

Journal